title: [Efficacy of Enalapril in patients with single kidney and with or without normoprotein diet].
abstract: BACKGROUND
  The patient with a solitary kidney and free protein intake can present pathological microalbuminuria.
  
  
  OBJECTIVE
  To evaluate the efficacy of Enalapril in patients with single kidney and with or without normoprotein diet.
  
  
  METHODS
  We studied 49 patients, mean age 11 years, eutrophics, with normal renal function and with approved medical consent. The exclusion criteria were: uropathies, arterial hypertension, malignant diseases, orthostatic proteinuria and previous treatments with nephrotoxics drugs. Patients were classified in two groups: Group A: with normoprotein diet (0.8 to 1.2 g/kg/day). Group B: with free protein intake. The patients with abnormal microalbuminuria received Enalapril (doses between 0.1-0.3 mg/kg/ day).
  
  
  RESULTS
  Group A: 21 patients, 2 with abnormal microalbuminuria. Mean increase of the renal size 14% (SD 8), risk of presenting pathological microalbuminuria: 9%. Group B: 28 patients, 11 with pathological microalbuminuria. Mean increase of the renal size: 33.8% (SD 6.1), risk of presenting abnormal microalbuminuria: 40%. RR: 4.125 (CI 1-16) (p: 0.01). NND: 3. Mean range of microalbuminuria pre- Enalapril 50 microg/min and post-Enalapril 11 microg/ min. Mean doses of Enalapril: 0.2 mg/kg/day. Correlation coefficient between increase of renal size and microalbuminuria range: 0.75 and between increase renal size and protein intake: 0.72. Mean time to reach abnormal microalbuminuria: 81 months (DS 7).
  
  
  CONCLUSIONS
  Enalapril together with the normoprotein diet in patient with single kidney reduces the risk of developing abnormal microalbuminuria.
authors.affiliation: Servicio de Nefrología, Hospital de Niños Dr. Ricardo Gutiérrez, Buenos Aires. Jliern@yahoo.com
authors.forename: Miguel
authors.initials: M
authors.lastname: Liern
authors.forename: Laura
authors.initials: L
authors.lastname: Maldonado
authors.forename: Pablo
authors.initials: P
authors.lastname: Jordán
authors.forename: Graciela
authors.initials: G
authors.lastname: Vallejo
mesh_terms: D000293:Adolescent; D000419:Albuminuria / Q000188:drug therapy*; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D002648:Child; D004044:Dietary Proteins; D004656:Enalapril / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007668:Kidney; D008297:Male; D012189:Retrospective Studies
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D004044:Dietary Proteins; D004656:Enalapril